Tert-butyl 4-(5-bromo-2-methyl-1,2,4-triazol-3-yl)piperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Tert-butyl 4-(5-bromo-2-methyl-1,2,4-triazol-3-yl)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(5-bromo-2-methyl-1,2,4-triazol-3-yl)piperidine-1-carboxylate
• 化学式: C₁₃H₂₁BrN₄O₂
• 分子量: 345.239
• InChiKey: PLNJGDDLRAUMNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  60.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Tert-butyl 4-(5-bromo-2-methyl-1,2,4-triazol-3-yl)piperidine-1-carboxylate 在 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 lithium chloride 作用下， 以 乙二醇二甲醚 、 异丙醇 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold

  摘要：

  Starting from compound 1, a potent PI3K alpha inhibitor having poor general kinase selectivity, we used structural data and modelling to identify key exploitable differences between PI3K alpha and the other kinases. This approach led us to design chemical modifications of the central pyrazole, which solved the poor kinase selectivity seen as a strong liability for the initial compound 1. Amongst the modifications explored, a 1,3,4-triazole ring (as in compound 4) as a replacement of the initial pyrazole provided good potency against PI3Ka, with excellent kinase selectivity. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.04.084
• 作为产物：
  描述：

  C₁₃H₁₉BrN₄O₂ 在 platinum(IV) oxide 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以51%的产率得到Tert-butyl 4-(5-bromo-2-methyl-1,2,4-triazol-3-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold

  摘要：

  Starting from compound 1, a potent PI3K alpha inhibitor having poor general kinase selectivity, we used structural data and modelling to identify key exploitable differences between PI3K alpha and the other kinases. This approach led us to design chemical modifications of the central pyrazole, which solved the poor kinase selectivity seen as a strong liability for the initial compound 1. Amongst the modifications explored, a 1,3,4-triazole ring (as in compound 4) as a replacement of the initial pyrazole provided good potency against PI3Ka, with excellent kinase selectivity. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.04.084

文献信息

• CHEMICAL COMPOUNDS
  申请人：ASTRAZENECA AB

  公开号：US20140206700A1

  公开（公告）日：2014-07-24

  The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R 1 and R 2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

  这项发明涉及公式(I)的化合物或其药用盐，其中R1和R2具有在描述中定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在治疗细胞增殖性疾病中的用途。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2014114928A1

  公开（公告）日：2014-07-31

  The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

  该发明涉及Formula (I)的化合物（Formula (I)）或其药用盐，其中R1和R2具有在描述中定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在治疗细胞增殖性疾病中的用途。
• Chemical Compounds
  申请人：AstraZeneca AB

  公开号：US20160137634A1

  公开（公告）日：2016-05-19

  The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R 1 and R 2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

  本发明涉及公式(I)的化合物或其药学上可接受的盐，其中R1和R2具有本说明书中定义的任何含义；它们的制备过程，包含它们的制药组合物以及它们在治疗细胞增殖性疾病方面的用途。
• US9156831B2
  申请人：——

  公开号：US9156831B2

  公开（公告）日：2015-10-13
• US9657008B2
  申请人：——

  公开号：US9657008B2

  公开（公告）日：2017-05-23